Search

Your search keyword '"Cholesterol, LDL therapeutic use"' showing total 89 results

Search Constraints

Start Over You searched for: Descriptor "Cholesterol, LDL therapeutic use" Remove constraint Descriptor: "Cholesterol, LDL therapeutic use"
89 results on '"Cholesterol, LDL therapeutic use"'

Search Results

1. Improving cardiovascular control in a hypertensive population in primary care. Results from a staff training intervention.

2. Optimal Medical Therapy for Stable Ischemic Heart Disease in 2024: Focus on Blood Pressure and Lipids.

3. Treatment of pediatric heterozygous familial hypercholesterolemia 7 years after the EAS recommendations: Real-world results from a large French cohort.

4. Weight and metabolic changes among virally suppressed people with HIV who switched to co-formulated bictegravir/emtricitabine/tenofovir alafenamide.

5. Evinacumab-dgnb (Evkeeza-REGN1500), A Novel Lipid-Lowering Therapy for Homozygous Familial Hypercholesterolemia.

6. Long-Lasting Control of LDL Cholesterol Induces a 40% Reduction in the Incidence of Cardiovascular Events: New Insights from a 7-Year Study.

7. The genetics of autosomal dominant familial hypercholesterolemia.

8. LP(a): Structure, Genetics, Associated Cardiovascular Risk, and Emerging Therapeutics.

9. Targeted Degradation of PCSK9 In Vivo by Autophagy-Tethering Compounds.

10. PCSK9 inhibitor use during pregnancy in a case of familial hypercholesterolemia complicated with coronary artery disease.

11. Medication Adherence With Polypill in Cardiovascular Disease and High-Risk Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Involving 7364 Participants.

12. Icariin alleviates high-fat diet-induced nonalcoholic fatty liver disease via up-regulating miR-206 to mediate NF-κB and MAPK pathways.

13. Moderate-Intensity Rosuvastatin/Ezetimibe Combination versus Quadruple-Dose Rosuvastatin Monotherapy: A Meta-Analysis and Systemic Review.

14. Characteristics of Coronary Atherosclerosis Related to Plaque Burden Regression During Treatment With Alirocumab: The ARCHITECT Study.

15. Antihyperlipidemic Treatment Options in Statin Resistance and Intolerance.

16. Comparison of the efficacy and safety of Shanhuang Jiangzhi tablets and atorvastatin in the treatment of patients with hyperlipidaemia.

17. Four kinds of traditional Chinese exercise therapy in the treatment of type 2 diabetes: a systematic review and network meta-analysis.

18. Construction of a Nomogram Model to Identify Atherosclerotic Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus.

19. Population PK/PD modeling of low-density lipoprotein cholesterol response in hypercholesterolemic participants following administration of bococizumab, a potent anti-PCSK9 monoclonal antibody.

20. Green synthesized silver nanoparticles for the treatment of diabetes and the related complications of hyperlipidemia and oxidative stress in diabetic rats.

21. Pharmacokinetic/LDL-C and exposure-response analysis of tafolecimab in Chinese hypercholesterolemia patients: Results from phase I, II, and III studies.

22. Influence of Gegenqinlian decoction on pharmacokinetics and pharmacodynamics of saxagliptin in type 2 diabetes mellitus rats.

23. Effect of Grape Seed Procyanidins Combined with Allicin on Lipid Levels in Hyperlipidemic Rats.

24. Crucial safety issues on Janus kinase inhibitors in rheumatoid arthritis might be associated with the lack of LDL-cholesterol management: a reasoned literature analysis.

25. [Evolocumab (Repatha®) : new therapy ofhypercholesterolaemia for secondary prevention of atherosclerotic disease].

26. Effect of atorvastatin on subclinical atherosclerosis in virally-suppressed HIV-infected patients with CMV seropositivity: a randomized double-blind placebo-controlled trial.

27. Alirocumab and plaque volume, calf muscle blood flow, and walking performance in peripheral artery disease: A randomized clinical trial.

28. Impact of ezetimibe on markers of inflammation in patients treated with statins: a systematic review.

29. Dietary intervention for children and adolescents with familial hypercholesterolaemia.

30. Effect of alirocumab on cataracts in patients with acute coronary syndromes.

31. Pharmacotherapeutics for dyslipidemia management.

32. Safety Issues Associated With the Clinical Application of PCSK9 Inhibitors: Current Findings.

33. Approach to patients with elevated low-density lipoprotein cholesterol levels.

34. Case Series of Genetically Confirmed Index Cases of Familial Hypercholesterolemia in Primary Care.

35. Efficacy of Mobile-Based Cognitive Behavioral Therapy on Lowering Low-density Lipoprotein Cholesterol Levels in Patients With Atherosclerotic Cardiovascular Disease: Multicenter, Prospective Randomized Controlled Trial.

36. Guanxinping ameliorates atherosclerosis via MAPK/NF-κB signaling pathway in ApoE -/- mice.

37. [Impact of orthotopic liver transplantation on serum lipid level and growing development in patients with homozygous or compound heterozygous familial hypercholesterolemia].

38. Impact of evolocumab on the pharmacodynamic profiles of clopidogrel in patients with atherosclerotic cardiovascular disease: a randomised, double-blind, placebo-controlled study.

39. Hypercholesterolemia in the Malaysian Cohort Participants: Genetic and Non-Genetic Risk Factors.

40. How Genetic Variants in Children with Familial Hypercholesterolemia Not Only Guide Detection, but Also Treatment.

41. Do Statins Counteract the Effect of Antidiabetic Drugs? Results of the SCEAD Study.

42. Gene and cell therapy approaches for familial hypercholesterolemia: An update.

43. [Efficacy and safety of various doses of hybutimibe monotherapy or in combination with atorvastatin for primary hypercholesterolemia: a multicenter, randomized, double-blind, double-dummy, parallel-controlled phase Ⅲ clinical trial].

44. Neoadjuvant docetaxel, epirubicin, and cyclophosphamide with or without metformin in breast cancer patients with metabolic abnormality: results from the randomized Phase II NeoMET trial.

45. Long-term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia.

46. Enterococcus faecium R-026 combined with Bacillus subtilis R-179 alleviate hypercholesterolemia and modulate the gut microbiota in C57BL/6 mice.

47. A Systematic Review of Randomized Clinical Trials on the Efficacy and Safety of Pitavastatin.

48. [Inclisiran (Leqvio®), a potent cholesterol-lowering agent by inhibiting PCSK9 using small interfering RNA-based innovative therapy].

49. Lipid Lowering Therapy: An Era Beyond Statins.

50. Androgens and low density lipoprotein-cholesterol interplay in modulating prostate cancer cell fate and metabolism.

Catalog

Books, media, physical & digital resources